Journal of Hepatology
Volume 33, Issue 3 , Pages 361-370 , September 2000

A study of fatty liver disease and plasma lipoproteins in a kindred with familial hypobetalipoproteinemia due to a novel truncated form of apolipoprotein B (APO B-54.5)

  • Patrizia Tarugi

      Affiliations

    • Corresponding Author InformationPatrizia Tarugi, Dipartimento di Scienze Biomediche, Università di Modena, Via Campi 287, I-41100 Modena, Italy. Tel. 39 059 428 613/428 629. Fax. 39 059 428 623.
    • Dipartimento di Scienze Biomediche, Università di Modena, Italy
    • The first two authors contributed equally to this work.
    • ,
  • Amedeo Lonardo

      Affiliations

    • Divisione di Medicina Interna e Gastroenterologia, Ospedale Civile, Modena, Italy
    • The first two authors contributed equally to this work.
    • ,
  • Giorgia Ballarini

      Affiliations

    • Dipartimento di Scienze Biomediche, Università di Modena, Italy
    • ,
  • Laura Erspamer

      Affiliations

    • Dipartimento di Scienze Biomediche, Università di Modena, Italy
    • ,
  • Emilio Tondelli

      Affiliations

    • Servizio di Radiologia, Ospedale Civile, Modena, Italy
    • ,
  • Stefano Bertolini

      Affiliations

    • Dipartimento di Medicina Interna, Università di Genova, Italy
    • ,
  • Sebastiano Calandra

      Affiliations

    • Dipartimento di Scienze Biomediche, Università di Modena, Italy

Received 15 July 1999 ,Revised 18 January 2000 ,Accepted 8 February 2000.

References 

  1. Sidney S, Farquhar JW. Cholesterol, cancer, and public health policy. Am J Med. 1983;75:494–508
  2. Yano K, Reed DM, MacLean CJ. Serum cholesterol and hemorrhagic stroke in the Honolulu heart program. Stroke. 1989;20:1460–1465
  3. Isles CG, Hole DJ, Gillis CR, Hawthorne VM, Lever AF. Plasma cholesterol, coronary heart disease, and cancer in the Renfrew and Paisley survey. Br Med J. 1989;298:920–928
  4. Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee D-J, Sherwin R, et al.  Multiple risk factor intervention trial research group. Serum cholesterol level and mortality findings for men screened in the multiple risk factor intervention trial. Arch Intern Med. 1992;152:1490–1500
  5. Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, McMillan G, et al.  Report of the conference on low blood cholesterol: mortality associations. Circulation. 1992;86:1046–1060
  6. Smith GD, Shipley MJ, Marmot MG, Rose G. Plasma cholesterol concentration and mortality. JAMA. 1992;267:70–76
  7. Glueck CG, Kelley W, Gupta A, Fontaine RN, Wang P, Gartside PS. Prospective 10-year evaluation of hypobetalipoproteinemia in a cohort of 772 firefighters and cross-sectional evaluation of hypocholesterolemia in 1,479 men in the National Health and Nutrition examination survey I. Metabolism. 1997;46:625–633
  8. Welty FK, Lahoz C, Tucker L, Ordovas JN, Wilson PWF, Schaefer EJ. Frequency of apo B and apo E gene mutation as causes of hypobetalipoproteinemia in the Framingham offspring population. Arterioscler Thromb Vasc Biol. 1998;18:1745–1751
  9. Kane GP, Havel RJ. Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins. In:  Scriver CR,  Beaudet AL,  Sly WS,  Valle D editor. The Metabolic and Molecular Basis of Inherited Disease, vol 2, 7th ed.. New York: McGraw Hill; 1995;p. 1853–1885
  10. Wetterau JR, Lin MCM, Jamil H. Microsomal triglyceride transfer protein. Biochim Biophys Acta. 1997;1345:136–150
  11. Dannoura AH, Berriot-Varoqueaux N, Amati P, Abadie V, Verthier N, Schmitz J, et al.  Anderson's disease. Exclusion of apolipoprotein and intracellular lipid transport genes. Arteriocler Thromb Vasc Biol. 1999;19:2494–2508
  12. Linton MRF, Farese RV, Young SG. Familial hypobetalipoproteinemia. J Lipid Res. 1993;34:521–541
  13. Kane JP, Hardman DA, Paulus HE. Heterogeneity of apolipoprotein B: isolation of a new species from human chylomicrons. Proc Natl Acad Sci USA. 1980;77:2465–2469
  14. Parhofer KG, Barrett PHR, Aguilar-Salinas CA, Schonfeld G. Positive linear correlation between the length of truncated apolipoprotein B and its secretion rate: in vivo studies in human apo B-89, apo B-75, apo B-54.8 and apo B-31 heterozygotes. J Lipid Res. 1996;37:844–852
  15. Farese RV, Garg A, Pierotti VR, Vega GL, Young SG. A truncated species of apolipoprotein B, B-83, associated with hypobetalipoproteinemia. J Lipid Res. 1992;33:569–577
  16. Hagve TA, Myrseth LE, Schrumpf E, Blomhoff JP, Christophersen B, Elgjo K, et al  Liver steatosis in hypobetalipoproteinemia. J Hepatol. 1991;13:104–111
  17. Wishingrad M, Paaso B, Garcia G. Fatty liver due to heterozygous hypobetalipoproteinemia. Am J Gastroenterol. 1994;89:1106–1107
  18. Castellano G, Garfia C, Gomez-Coronado D, Arenas J, Manzanares J, Colina F, et al.  Diffuse fatty liver in familial heterozygous hypobetalipoproteinemia. J Clin Gastroenterol. 1997;25:379–382
  19. Ogata H, Akagi K, Baba M, Nagamatsu A, Suzuki N, Nomiyama K, et al.  Fatty liver in a case with heterozygous familial hypobetalipoproteinemia. Am J Gastroenterol. 1997;92:339–342
  20. Mehta NN, Desai HG. Persistent transaminase elevation due to heterozygous (familial) apolipoprotein B deficiency. Indian J Gastroenterol. 1997;16:158–159
  21. Ahmed A, Keeffe EB. Asymptomatic elevation of aminotransferase levels and fatty liver secondary to heterozygous hypobetalipoproteinemia. Am J Gastroenterol. 1998;93:2598–2599
  22. Tarugi P, Lonardo A, Ballarini G, Grisendi A, Pulvirenti M, Bagni A, et al.  Fatty liver in heterozygous hypobetalipoproteinemia caused by a novel truncated form of apolipoprotein B. Gastroenterology. 1996;111:1125–1133
  23. Lonardo A, Tarugi P, Ballarini G, Bagni A. Familial heterozygous hypobetalipoproteinemia, extrahepatic primary malignancy, and hepatocellular carcinoma. Dig Dis Sci. 1998;43:2489–2492
  24. Ogawa Y, Murata Y, Nishioka A, Inomata T, Yoshida S. Tamoxifen-induced fatty liver in patient with breast cancer. Lancet. 1998;351:725
  25. Saibara T, Onishi S, Ogawa Y, Yoshida S, Enzan H. Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis. Lancet. 1999;353:1802
  26. Chapman MJ, Goldstein S, Lagrange D, Laplaud PM. A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. J Lipid Res. 1981;22:339–358
  27. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin fenol reagent. J Biol Chem. 1951;193:265–275
  28. Schumaker VN, Puppione DL. Sequential flotation ultracentrifugation. Methods Enzymol. 1986;128:155–170
  29. Tarugi P, Albertazzi L, Nicolini S, Calandra S. Absence of apolipoprotein B-48 in the chick, Gallus domesticus. J Lipid Res. 1990;31:417–427
  30. Tarugi P, Reggiani D, Ottaviani E, Ferrari St, Tiozzo R, Calandra S. Plasma lipoproteins, tissue cholesterol overload, and skeletal muscle apolipoprotein A- I synthesis in the developing chick. J Lipid Res. 1989;30:9–22
  31. Tarugi P, Nicolini S, Ballarini G, Marchi L, Duvigneau C, Tartoni P, et al.  Synthesis and secretion of B-100 and A-I apolipoproteins in response to the changes of intracellular cholesteryl ester content in chick liver. J Lipid Res. 1996;37:493–507
  32. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning. A Laboratory Manual. Cold Spring Arbor: Cold Spring Laboratory; 1989;
  33. Ilmonen M, Helio T, Ebeling T, Pyorala K, Uusitupa M, Palotie A, et al.  Screening for mutations in the exon 26 of the apolipoprotein B gene in hypercholesterolemic Finnish families by the single-strand conformation polymorphism method. Hum Mut. 1994;4:217–223
  34. Knott TJ, Wallis SC, Powell LM, Pease RJ, Lusis AJ, Blackhart B, et al.  Complete cDNA and derived protein sequence of human apolipoprotein B-100. Nucleic Acid Res. 1986;14:7501–7503
  35. Boerwinkle E, Chan L. A three codon insertion/deletion polymorphism in the signal peptide region of the human apolipoprotein B (APOB) gene directly typed by the polymerase chain reaction. Nucleic Acid Res. 1989;17:4003
  36. Huang L-S, Gavish D, Breslow JL. Sequence polymorphism in the human apo B gene at position 8344. Nucleic Acid Res. 1990;18:5922
  37. Leren TP, Bakken KS, Hoel V, Hjermann I, Berg K. Screening for mutations of the apolipoprotein B gene causing hypocholesterolemia. Hum Genet. 1998;102:44–49
  38. Karpe F, Lundahl B, Ehrenborg E, Eriksson P, Hamsten A. A common functional polymorphism in the promoter region of the microsomal triglyceride transfer protein gene influences plasma LDL levels. Arterioscler Thromb Vasc Biol. 1998;18:756–761
  39. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31:545–548
  40. Gardemann A, Ohly D, Fink M, Katz N, Tillmanns H, Hehrlein FW, et al.  Association of the insertion/deletion gene polymorphism of the apolipoprotein B signal peptide with myocardial infarction. Atherosclerosis. 1998;141:167–175
  41. Humphries SE, Peacock R, Gudnason V. Genetic determinants of hyperlipidemia. In:  Betteridge DJ,  Illingworth DR,  Shepherd J editor. Lipoproteins in Health and Disease. London: Arnold; 1999;p. 127–162
  42. Graham LD, Knott TJ, Jones TC, Pease RJ, Pullinger CR, Scott J. Carboxyl-terminal truncation of apolipoprotein B results in gradual loss of the ability to form buoyant lipoproteins in cultured human and rat liver cell lines. Biochemistry. 1991;30:5616–5621
  43. Herscovitz H, Hadsopoulou-Cladaras M, Walsh MT, Cladaras C, Zannis V, Small DM. Expression, secretion, and lipid-binding characterisation of the N-terminal 17% of apolipoprotein B. Proc Natl Acad Sci (USA). 1991;88:7313–7317
  44. Yao Z, Blackhart BD, Linton MF, Taylor SM, Young SG, McCarthy BJ. Expression of carboxyl-terminally truncated forms of human apolipoprotein B in rat hepatoma cells. J Biol Chem. 1991;266:3300–3308
  45. McLeod RS, Zhao Y, Selby SL, Westerlund J, Yao Z. Carboxylterminal truncation impairs lipid recruitment by apolipoprotein B-100 but does not affect secretion of the truncated B-containing lipoproteins. J Biol Chem. 1994;269:2852–2862
  46. Elias N, Patterson BW, Schonfeld G. Decreased production rates of VLDL triglycerides and apo B-100 in subjects heterozygous for familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol. 1999;19:2714–2721
  47. Maher JJ. Alcoholic liver disease. In:  Sleisenger MH,  Fordtran JS editor. Gastrointestinal and Liver Disease, vol 2, 6th ed.. Philadelphia: WB Saunders Company; 1998;p. 1199–1214
  48. Lonardo A. Fatty liver and nonalcoholic steatohepatitis: where do we stand and where are we going?. Dig Dis. 1999;17:80–89
  49. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al.  Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107:450–455
  50. Wagner RD, Krul ES, Tang J, Parhofer KG, Garlock K, Talmud P, et al.  Apo B-54.8, a truncated apolipoprotein found primarily in VLDL, is associated with a nonsense mutation in the apo B gene and hypobetalipoproteinemia. J Lipid Res. 1991;32:1001–1011
  51. Groenewegen WA, Krul ES, Schonfeld G. Apolipoprotein B-52 mutation associated with hypobetalipoproteinemia is compatible with a misaligned pairing deletion mechanism. J Lipid Res. 1993;34:971–981
  52. Young SG, Pullinger CR, Zysow BR, Hofmann-Radvani H, Linton MR, Farese RV, et al.  Four new mutations in the apolipoprotein B gene causing hypobetalipoproteinemia, including two different frameshift mutations that yield truncated apolipoprotein B protein of identical length. J Lipid Res. 1993;34:501–507
  53. Aguilar-Salinas CA, Barrett PHR, Parhofer KG, Young SG, Tessereau D, Bateman J, et al.  Apoprotein B-100 production is decreased in subjects heterozygous for truncations of apoprotein B. Arterioscler Thromb Vasc Biol. 1995;15:71–80
  54. Kim E, Cham CM, Veniant MM, Ambroziak P, Young SG. Dual mechanisms for the low plasma levels of truncated apolipoprotein B proteins in familial hypobetalipoproteinemia. J Clin Invest. 1998;101:1468–1477
  55. Sturley SL, Talmud PJ, Brasseur R, Culbertson MR, Humphries SE, Attie AD. Human apolipoprotein B signal sequence variants confer a secretion-defective phenotype when expressed in yeast. J Biol Chem. 1994;269:21670–21675
  56. Weisgraber KH, Innerarity TL, Mahley RW. Abnormal lipoprotein-receptor-binding activity of the human E apolipoprotein due to cysteine-arginine interchange at a single site. J Biol Chem. 1982;257:2518–2521
  57. Kowal RC, Herz J, Goldstein JL, Esser V, Brown MS. Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apolipoprotein E-enriched lipoproteins. Proc Natl Acad Sci USA. 1989;86:5810–5814

PII: S0168-8278(00)80270-6

Journal of Hepatology
Volume 33, Issue 3 , Pages 361-370 , September 2000

Article Tools

* Image Usage & Resolution